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THE USE OF EPINEPHRINE IN CARDIAC RESUSCITATION AND ITS ROLE 
IN ANOXIC BRAIN DAMAGE 
ABSTRACT 
 Cardiac arrest is a lethal condition that can arise from numerous underlying 
etiologies. Cardiopulmonary resuscitation (CPR) is the centerpiece of its treatment for 
healthcare professionals and lay people alike. Several medications have been investigated 
as a potential treatment for cardiac arrests over the years but only epinephrine has been 
used as a mainstay treatment for all causes of cardiac arrest. However, this treatment was 
adopted as the gold standard prior to any thorough assessment of its efficacy or safety. In 
recent years there have been growing concerns in the scientific community that 
epinephrine may further propagate anoxic brain damage and may not be as efficacious as 
originally believed. Epinephrine is proposed to increase blood pressure and heart rate, 
which may increase the probability of achieving return of spontaneous circulation 
(ROSC). However, this may come at the cost of an increased risk of stroke and oxygen 
demand, thereby causing additional anoxic brain damage.  While there have been a few 
studies that investigated the efficacy of epinephrine, few have explored the impact it may 
have on a patient’s neurological status following a cardiac arrest. None of the studies 
focused on the neurological outcome of cardiac arrest patients due to the use of 
epinephrine had the proper sample size or power to properly assess epinephrine’s role. 
Additionally, in these studies the neurological outcome was not the primary endpoint and, 
as such, there was limited data collected to analyze neurological status. The proposed 
double-blind randomized controlled trial will compare epinephrine and placebo by 
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assessing the neurological status of cardiac arrest patients prior to hospital discharge. By 
including imaging and standardized testing this study hopes to build upon those studies 
that first raised the question of epinephrine’s safety. With this thorough investigation of 
epinephrine’s role in anoxic brain damage during cardiac arrest, a greater understanding 
of epinephrine’s risks and benefits can be developed. This will allow for epinephrine’s 
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Cardiac arrest is a lethal condition that affects over half a million Americans annualy. 
Almost 90% of individuals who suffer a cardiac arrest will die and many of those who 
survive will suffer crippling neurological damage.19 While several adjuvant therapies 
have been tested over the years, the treatment of cardiac arrest has largely remained 
unchanged. Current treatment involves CPR, defibrillation and medications.  
Epinephrine is one such medication that has been used throughout modern 
medicine. It is the most widely used medication in cardiac arrest and is applicable to all 
forms of cardiac arrest. Yet despite its widespread and continued use, there is limited data 
to support its efficacy. While some studies have investigated its efficacy, many of the 
studies have yielded conflicting results. Additionally, there have been even fewer studies 
conducted that investigated its safety, specifically the impact it may have on the 
neurological outcome of survivors. Recently concerns have been raised about its safety 
and studies have started to investigate its role in anoxic brain damage.  
 
Statement of the Problem 
Epinephrine has been used for over 60 years to treat cardiac arrest without first having 
been proven safe through randomized controlled trials (RCTs)13. While some studies 
have investigated efficacy and survival, few studies have considered the neurological 
outcome of patients. Growing concerns over epinephrine administration in cardiac arrests 
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has resulted in an increased interest in investigating how it may contribute to anoxic brain 
damage, which ultimately results in neurological deficits in survivors. 
 At this point in time, there has not been a placebo-controlled RCT of epinephrine 
that uses survival with favorable neurological outcome as the primary endpoint of the 
study. Furthermore, existing studies have failed to characterize the exact nature of 
observed neurological deficits or illustrate which parts of the brain are affected. No 
comparisons in trends of neurological deficit and brain damage have been made between 
survivors of cardiac arrest who have received epinephrine and those who have not. 
Additionally, all attempts to evaluate neurological outcome thus far have been based 
solely on a subjective evaluation of the patient. This subjective basis allows for bias and 
detracts from the power of the findings. 
 
Hypothesis 
While epinephrine may have a short-term benefit in survival, it leads to increased risk of 
neurological deficits and anoxic brain damage.  
 
Objectives and specific aims 
The goal of this study is to further characterize anoxic brain damage that occurs 
intrinsically with cardiac arrest and the anoxic brain damage that occurs as a direct result 
of giving epinephrine.  
By introducing objective means of categorizing neurological deficits and by 
identifying regions of the brain most affected, a clearer picture of epinephrine’s role in 
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anoxic brain damage will be painted. In turn, this will open the door for future studies to 
more accurately weigh the risks and benefits of administering epinephrine during a 
cardiac arrest. Specifically, this study aims to: 
● Compare epinephrine and placebo in a randomized controlled trial with favorable 
neurological outcome as the primary outcome 
● Establish objective data to analyze neurologic status 
● Further characterize trends in neurological deficits and affected brain regions that 





REVIEW OF THE LITERATURE 
Overview 
Cardiac arrest is a potentially lethal condition defined as an abrupt impairment of 
heart the heart’s normal function, resulting in the loss of a pulse and the ability to 
adequately circulate blood throughout the body.44 When it does not lead to death, a large 
proportion of survivors have high rates of morbidity including brain damage due to a lack 
of oxygen from decreased blood flow. Cardiac arrest has been the subject of several 
research studies because of this associated severe morbidity and mortality.  
As cardiac arrest is a condition that can arise from multiple disease processes, 
calculating its incidence is difficult. Because cardiac arrest can arise from so many 
underlying conditions, hospital records often reflect diagnosis codes of the underlying 
diseases rather than cardiac arrests”21. Fortunately, some reliable organizations have 
made some widely accepted estimates for the incidence of cardiac arrest. The CDC 
estimates that approximately 209,000 people suffer an in-hospital cardiac arrest every 
year in the United States.5 In addition to the 209,000 patients who suffer cardiac arrests 
while already hospitalized for other reasons, the Sudden Cardiac Arrest Foundation 
estimates that there are at least an additional 356,000 out-of-hospital cardiac arrests 
annually.20 Together this means that roughly 565,000 Americans suffer cardiac arrests 
each year, making this an important subject to understand and investigate. Despite the 
fact that in-hospital and out-of-hospital cardiac arrests are treated in the same fashion, 




 In-hospital cardiac arrests have access to earlier medical care, superior medical 
equipment and more experienced medical personnel. In-hospital cardiac arrests often 
have a near immediate recognition of cardiac arrest and a rapid initiation of CPR and 
initiation of the Advanced Cardiac Life Support protocol. In contrast, out-of-hospital 
cardiac arrests largely rely on layman witnesses to identify cardiac arrest, call 911 and 
initiate CPR. Unfortunately, most Americans are not CPR certified and only 18% of 
adults are CPR certified, suggesting that there is likely to be a significant difference in 
CPR quality between the two locations of cardiac arrests.20 In addition to a probable 
delay in identification of cardiac arrest and initiation of CPR, on average in the United 
States it takes emergency medical services (EMS) personnel about 7 minutes to arrive at 
the scene after the 911 call; this time is prolonged to an average of about 14 minutes in 
more rural settings8. This prolonged response time for medical personnel often results in 
a delay in defibrillation as well, in those cardiac arrests that require defibrillation. This is 
critical because for every minute delay in defibrillation, the odds of survival are estimated 
to decrease by 7% to 10%.31 The EMS team responding to a potential cardiac arrest 
usually includes the driver, an emergency technician and a paramedic. While the 
paramedic is able to intubate, establish intravenous access and administer epinephrine, 
these actions have the potential of interfering with good quality CPR. In comparison, in-
hospital cardiac arrest patients already have intravenous access, are already on telemetry 
and have a full medical team assisting with each member having a specified role.  
These differences play a critical role in the outcome of cardiac arrest patients. 
According to the American Heart Association in 2016, 24.8% of in-hospital cardiac arrest 
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patients survived to hospital discharge, while only 12% of out-of-hospital cardiac arrest 
patients survived to hospital discharge19. Because of the intrinsic differences between 
these two groups and logistical issues with recruitment, almost every clinical trial that 
investigates variables that may influence cardiac arrest outcome separates these two 
populations. While this variable drastically affects the outcome of cardiac arrest patients, 
the underlying pathology remains the same. 
While all cardiac arrests result in loss of heart function, causing a halt in blood 
circulation and pulse, there are many causes of cardiac arrest. Any potential lethal 
disease, condition or environmental factor can potentially lead to cardiac arrest. However, 
they do not directly cause the blood to stop flowing throughout the body. These 
underlying conditions cause stress on the heart, which under dire circumstances can cause 
an arrhythmia, can ultimately compromise the heart’s ability to appropriately push blood 
throughout the body. However, some potential underlying conditions are more important 
than others to identify. There are some causes of cardiac arrest that are reversible, known 
as the H’s and T’s of ACLS (Table 1). This is important as early detection and correction 
of these abnormalities in certain cases can result in a higher survival rate than non-
reversible or other medical causes of cardiac arrest11. However, regardless of the 
underlying medical condition that resulted in the arrhythmia, the arrhythmia is the issue 






Table 1. Reversible Causes of Cardiac Arrest 
Hypovolemia Toxins 
Hypoxia Tamponade 
Hydrogen ions (Acidosis) Tension Pneumothorax 
Hypokalemia / Hyperkalemia Thrombosis (Cardiac) 
Hypothermia Thrombosis (Pulmonary) 
 
There are four types of heart rhythms that can be present during a cardiac arrest: 
Pulseless Electrical Activity (PEA), Asystole, Unstable Ventricular Tachycardia (VT) 
and Ventricular Fibrillation (VF). The American Heart Association defines asystole as an 
absence of electrical activity, which results in an inability of the heart to contract.19 The 
defining characteristic of asystole is a lack of both electrical activity and cardiac 
contractions. PEA is characterized by an organized rhythm sustaining sufficient electrical 
activity to initiate a heartbeat but without a corresponding cardiac contraction to perfuse 
the body or to palpate a pulse12. Thus, the main distinguishing difference between PEA 
and asystole is that, while they both lack an adequate heartbeat, PEA does have a 
recognizable heart rhythm and sufficient electrical activity to cause a heartbeat under 
normal conditions.  
 Under normal conditions the electrical impulse starts in the sinoatrial node (SA) 
in the right atrium of the heart. This node emits a rapid electrical impulse that travels 
through the atrial wall causing an organized atrial contraction and continues until it 
reaches the atrioventricular (AV) node, located at the junction of all four chambers of the 
heart. The AV node then sends out an impulse to the bundle of His, which splits into two 
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electrical pathways along the ventricular septum. This in turn innervates one of the 
ventricles as the electrical impulse travels to the purkinje fibers at the apex (bottom) of 
the heart. This coordinated and organized electrical pathway results in a strong and 
organized heartbeat35.  
Normally, the AV node momentarily slows down the electrical signal, allowing 
blood to fill the ventricles before sending out a strong and organized electrical impulse36. 
VT is caused by an electrical impulse and corresponding contraction that starts in the 
ventricles of the heart in a location other than the AV node. This, in turn, does not allow 
the ventricles to fill with blood and causes premature, slower and weaker ventricular 
contraction. When three such consecutive ventricular impulses with corresponding 
ventricular contractions occur consecutively at a minimum rate of 100 beats per minute, 
the arrhythmia is considered to be VT. When VT lasts for 30 seconds or longer, it meets 
criteria of sustained VT2. However, VT does not always result in cardiac arrest as the 
ventricle is still contracting. When the heart rate and blood pressure drops below a 
sustainable level to maintain vital organ function, VT is considered unstable and meets 
criteria for cardiac arrest. When vital organ function is compromised, the patient can 
suffer symptoms such as altered mental status, chest pain, lightheadedness, syncope or  
shortness of breath. These symptoms are often used to classify the patient as unstable or 
stable34. When VT is left untreated, it often leads to the last arrhythmia that causes 
cardiac arrest36.  
VF is another arrhythmia that originates in the ventricles of the heart. However, 
while VT is a rapid and regular cardiac rhythm, VF is a rapid, uncoordinated, irregular 
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rhythm. VF occurs when multiple electrical impulses originate in different locations of 
the ventricles, causing the ventricular wall to quiver rather than contract1. In contrast to 
VT, which has the potential to sustain an adequate heartbeat to perfuse the body, VF 
lacks the contractility to generate enough force to pump blood through the body. 
Identifying these rhythms during cardiac arrest is critical as only VF and VT will 
respond to the shock emitted by an automated external defibrillator (AED). In VF and 
VT, the heart tissue is responding properly to an existing but impaired electrical current. 
The AED delivers a shock via the electrode pads through the patient’s chest wall and into 
the heart, which in turn momentarily stops all muscular contractions and cardiac activity. 
This halt in cardiac activity gives the heart an opportunity to restart the normal electrical 
current and ensuing organized cardiac contraction that originates with an impulse SA 
node31. For this reason, VF and VT are considered shockable rhythms, while PEA and 
asystole are non-shockable.  
Current treatment for all rhythms starts with the basic life support (BLS) protocol 
(Figure 1), which includes cardiopulmonary resuscitation (CPR) and defibrillation with 
an AED for shockable rhythms. BLS is the principal intervention for cardiac arrest and 
has demonstrated improved outcomes in cardiac arrest patients32. For adults, this consists 
of attaching an AED and initiating CPR. A cycle of CPR consists of 30 chest 
compressions with a depth of 2cm with proper chest recoil at a rate of 100 compressions 
per minute followed by 2 rescue breaths. A cycle is repeated 5 times over a 2-minute 
period. After two minutes of uninterrupted CPR, the primary provider will initiate a pulse 
check. If the heart rhythm analysis via the AED shows a shockable rhythm, a 
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defibrillation shock will be administered. When qualified medical personnel become 
available, care can progress to the advanced cardiac life support (ACLS) protocol (Figure 
2). Medical personnel will then follow the ACLS protocol in a cyclic fashion until either 
the patient is declared dead by the supervising provider or a pulse returns, known as the 
return of spontaneous circulation (ROSC).  
Figure 2. Basic Life Support (BLS) Protocol 
 




Figure 2. Advanced Cardiac Life Support (ACLS) Protocol 
 
-Extracted from the Massachusetts Department of Public Health33 
ACLS builds upon the BLS protocol by including the use of medications, 
placement of an advanced airway and treatment of reversible causes of cardiac arrest to 
improve the chance of resuscitating the patient. Several types of medication have been 
tried for the treatment of cardiac arrest. However, despite several studies investigating 
potential drugs that may improve cardiac arrest survival, there has been little evidence to 
support that such medications were effective13. Currently, only four medications are 
recommended for the acute treatment of cardiac arrest: amiodarone, lidocaine, 
magnesium sulfate and epinephrine. Similar to whether or not a defibrillation shock is 
used, the use of medications also depends on the underlying rhythm of the cardiac arrest.  
The ACLS protocol includes 5 cycles (2 minutes) of uninterrupted CPR followed 
by a pulse check and cardiac rhythm check. If the rhythm is found to be shockable, 
defibrillation will be administered and the next round of CPR will be resumed. If a non-
shockable rhythm is found, CPR is restarted with no defibrillation given. So long as no 
pulse is found during the pulse check, epinephrine (1mg) will be given every 3-5 minutes 
or after every other pulse/rhythm check starting after the first. In the case of shockable 
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rhythms, amiodarone (300mg for the initial dose and 150mg for ensuing doses) or 
lidocaine (1-1.5mg/kg) will be given every 3-5 minutes after the pulse/rhythm checks in 
which epinephrine will not be given after. This will be repeated for the duration of the 
cardiac arrest code28. 
Amiodarone is a class III antiarrhythmic that blocks the potassium channels 
responsible for repolarization. This in turn yields two effects. The first is that it raises the 
excitability threshold of the cardiac myocytes to lower the probability that the weaker 
alternative electrical pathways will elicit a cardiac contraction in comparison to the strong 
electrical impulse originating from the SA and AV nodes. The second is that it prolongs 
the refractory period of the cardiac myocyte. The refractory period is the period of time 
before repolarization is complete in which a myocyte cannot respond to another stimulus. 
Therefore, if the cardiac tissue is unable to respond to the rapid alternative pathway of VF 
or VT, the cycle of the arrhythmia can be broken10. 
Lidocaine is a class Ib antiarrhythmic that is used as an alternative to amiodarone 
in the treatment of shockable rhythms. Class Ib antiarrhythmic medications work by 
blocking the sodium channels and have a limited effect on the QT interval or QRS 
complex7. Lidocaine binds while the sodium channels are inactivated and rapidly 
dissociates during repolarization due to increased membrane potential and charge. Under 
normal circumstances, this results in little difference in the sodium channel function. 
However, during rapid stimulation such as in VF or VT, the membrane’s charge is not 
able to build quickly enough for lidocaine to dissociate prior to the next electrical 
impulse. When lidocaine is unable to dissociate, it blocks the next electrical impulse that 
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otherwise would have activated the sodium channel to create a depolarization effect that 
would result in a cardiac contraction29. Therefore, if enough sodium channels do not 
activate in response to the electrical impulse, a depolarization will not occur and neither 
will a cardiac contraction. This in turn causes a break in the cycle produced by VF and 
VT, allowing for an opportunity for the normal electrical pathway to take over. 
Magnesium sulfate is recommended only for the treatment of torsades de pointes 
in cardiac arrest. Torsades de pointes is a form of VT that is defined by a prolonged QT 
interval and the presence of U waves on an ECG, which is caused by a delay in 
repolarization. Therefore, by administering magnesium sulfate, the depolarization effect 
is restored, shortening the QT interval30. 
Epinephrine is the only medication that is recommended for all rhythms of cardiac 
arrest. Epinephrine is a vasopressor or sympathomimetic that functions by activating 
alpha and beta receptors found on muscles in one’s airways and cardiovascular system27. 
In cardiac arrest, epinephrine is used to increase cardiac contractility, heart rate and blood 
pressure.  
Epinephrine functions by binding to certain G-protein-coupled receptors, alpha 
and beta receptors, on smooth muscles and cardiac muscles26. This in turn causes a signal 
transduction cascade that results in a change to calcium influx into a cell via calcium 
channels in the cell membrane and the endoplasmic reticulum inside of the smooth 
muscles. Activation of alpha-1 receptors results in increased calcium influx which causes 
an increase in muscle tone. In the case of beta-2 receptor activation, calcium influx is 
decreased which will decrease muscle tone25.  
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One of epinephrine’s desired effects lies within the smooth muscles of the blood 
vessels. These smooth muscles are lined with both alpha-1 receptors and beta-2 receptors. 
However, activation of these two receptors result in opposite effects. Activation of beta-2 
receptors results in smooth muscle relaxation or vasodilation. Activation of alpha-1 
receptors results in smooth muscle contraction or vasoconstriction. Epinephrine has a 
much higher affinity for the beta-2 receptor than the alpha 1 receptors. However, smooth 
muscles are lined with many more alpha-1 receptors, relative to beta-2 receptors. This 
results in an unusual effect in which epinephrine at low dose binds to beta-2 receptors 
more readily and causes vasodilation, which in turn, causes a decrease in peripheral 
resistance and blood pressure. Meanwhile, when used in a high dose, such as a 1mg bolus 
given during cardiac arrest, the beta-2 receptors become saturated and epinephrine binds 
to alpha-1 receptors in large amounts, precipitating a vasoconstrictive effect, increasing 
the peripheral resistance and blood pressure25.  
Another desired effect comes from beta-1 receptors found in the heart. Unlike the 
alpha-1 and beta-2 receptors, beta-1 receptors are found on cardiac muscle. Similar to 
alpha-1 receptors, beta-1 activation uses a signal transduction pathway that results in an 
influx of intracellular calcium. The cells of the SA and AV nodes contain beta-1 
receptors, which regulate the cells’ excitability and rate of emitted electrical impulse. So 
by increasing the rate of these impulses, the heart rate is increased. Additionally, both 
atrial and ventricular cardiac myocytes contain beta-1 receptors. By activating these 
receptors, ventricular muscular firing is exaggerated through increased myosin activation 
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and cardiac contractility increases. By increasing heart rate and cardiac contractility, 
epinephrine increases both stroke volume and cardiac output24. 
While this mechanism is understood and widely accepted, epinephrine was 
adapted as the gold standard treatment of cardiac arrest prior to undergoing proper 
clinical trials to prove its efficacy and safety. As a result, epinephrine has been used 
during cardiac resuscitation for more than 50 years, despite limited evidence of efficacy 
or safety from randomized controlled trials (RCTs). However, in recent years there has 
been a growing concern about epinephrine’s efficacy and safety with its use during 
cardiac arrest. A systematic review and meta-analysis by Kempton et. al. examined five 
clinical trials of epinephrine in cardiopulmonary resuscitation in out-of-hospital cardiac 
arrests and found that epinephrine use was associated with increased ROSC and survival 
to hospital admission. However, they found no statistically significant improvement in 
survival to hospital discharge or survival with favorable neurological outcome. This study 
further broke down the population into two subgroups: shockable and non-shockable 
rhythms. By doing this, they found that there was a superior response to epinephrine if 
the underlying rhythm was non-shockable.9 
One of the most alarming morbidities associated with cardiac arrest survival is 
brain damage due to decreased blood and oxygen supply, also known as hypoxia or 
anoxic brain damage. A lack of oxygen causes a decrease in ATP production, the main 
energy source of a cell. Without ATP, the cells’ sodium-potassium pumps cannot 
function and the cell loses its ability to function properly. Additionally, it causes a release 
of glutamate that will affect NMDA receptors and cause excitotoxicity by increasing the 
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influx of calcium into the cell. The increase of intracellular calcium then impedes the 
electron transport chain and allows a buildup of oxygen-free radicals that cause further 
cellular damage and death23. 
 The brain is particularly vulnerable to hypoxia during cardiac arrest because 
while it only comprises 2 percent of body mass, the brain consumes 20% of the body’s 
oxygen supply.37 This high oxygen demand becomes dangerous when conditions limit the 
body’s ability to effectively circulate blood. While any part of the cerebrum may be 
affected, it is thought that certain parts of the brain are more susceptible to hypoxia than 
others. Based on studies of coma related injuries the most common areas of anoxic brain 
damage are: the cerebral cortex, cerebellum, hippocampus and basal ganglia.23 While 
these findings are based on coma patients and as a result may not be generalizable to 
cardiac arrest patients, it does provide a basis for further examination of this issue. 
The recently raised question of epinephrine’s safety largely is based on the 
possibility that it could potentially increase the risk of anoxic brain damage and 
neurological deficits. While alpha-1 receptor activation increases coronary blood flow 
and diastolic pressure resulting in an increased chance of ROSC, it also causes platelet 
activation. This increases the risk for clots, resulting in watershed brain damage. 
Additionally, beta activation could have potentially harmful side-effects as well. While 
beta-1 activation causes increased contractility and heart rate, this also increases 
myocardial oxygen demand and increases risk for arrhythmia under normal 
circumstances. As a result, it is possible that the harmful effects of epinephrine may 




Effect of Adrenaline on Survival in Out-of-Hospital Cardiac Arrest: A Randomized 
Double-Blind Placebo-Controlled Trial16 
Epinephrine has commonly been used during cardiopulmonary resuscitation for more 
than 60 years, despite limited evidence of efficacy or safety from randomized controlled 
trials (RCTs). However, in recent years, there have been growing concerns about 
potential anoxic brain injury as a result of epinephrine resulting in neurological deficits. 
A double blinded randomized controlled study by Jacobs et. al. was the first placebo-
controlled study to examine neurological function as a consequence of epinephrine 
administration during cardiopulmonary resuscitation. 
This randomized controlled study involved 534 patients suffering from out-of-
hospital cardiac arrest in Western Australia. Patients were randomly assigned to either 
receive epinephrine or placebo at the point in CPR when epinephrine would be used. 
Epinephrine or placebo would then be administered every 3 minutes until ROSC was 
achieved or CPR was terminated. Neurological outcome was evaluated at hospital 
discharge by stratifying patients into 5 cerebral performance categories based on a 
subjective score of 1-5. Good neurological outcome was defined as a score of 1-2 and 
poor neurological outcome defined as a score of 3-5. 
In this study 264 patients were placed in the epinephrine group and 256 in the 
placebo group. The placebo group yielded 5 (1.9%) survivors with good neurological 
outcome while the epinephrine group had 9 (3.3%) survivors with good neurological 
function (p=0.31). While this suggests an improved survival with good neurological 
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function in the epinephrine group, the improvement was not statistically significant. 
Additionally, the placebo group had no cases of survival to discharge with poor 
neurological function, while the epinephrine group had 2 patients (0.7%). No further 
analysis was made for poor neurological outcome. 
This study was a pioneer for the use of epinephrine during CPR trials but also 
raised an important question of whether neurological outcome is impacted by 
epinephrine. However, there were several shortfalls in this study. The primary outcome 
of this study was not neurological outcome but rather survival to hospital discharge. 
However, this study was underpowered for its primary outcome, which also means it was 
far too small of a sample size to identify any significant findings concerning neurological 
outcome. Also, this study was unable to assess CPR quality and epinephrine dosing 
interval, which could have helped normalize or account for potential confounding 
variables. While these confounding variables were randomized, there were only 16 
survivors who were assessed for neurological function. Thus, due to the small sample 
size, randomization is not enough to compensate for potential confounding variables. 
Lastly, paramedics joined the study voluntarily and were responsible for recruiting 
patients into the study, thus allowing for potential selection bias. While this study was too 
small to effectively assess for the neurological impact of epinephrine in cardiopulmonary 
resuscitation, it opened the door for other studies to further investigate this issue. 
 
A Randomized Trial of Epinephrine in Out-of-Hospital Cardiac Arrest13 
While a few studies have investigated the use of epinephrine during cardiopulmonary 
resuscitation and its potential effect on neurological outcome, they have failed to prove 
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that epinephrine has any significant impact on neurological outcome. However, a 
randomized controlled study by Perkins et. al. is the largest and latest study to examine 
the potential neurological impact that epinephrine may have on patients suffering from 
cardiac arrest. 
The randomized controlled trial involved 8,014 patients in out-of-hospital cardiac 
arrest through five ambulance services in the United Kingdom. In this double-blinded 
study, patients were randomly administered standard doses of epinephrine (1mg) or saline 
placebo every 3-5 minutes and then evaluated for 30-day survival and neurological 
outcome based on the modified Rankin scale. Only nonpregnant adults older than 16 
years old were included and cardiac arrests due to anaphylaxis or asthma were excluded. 
This scale stratified patients based on neurological function on a scale of 0-6 with scores 
of 0-3 considered to be favorable neurological outcome and 4-6 being considered poor 
neurological outcome. These binary values were then used to create an odds ratio and a 
95% confidence interval.  
In this study 4,007 patients were given epinephrine, yielding 87 cases (2.2%) of 
survival with favorable neurological outcome at discharge. Out of the 3,994 patients 
given placebo, 74 patients (1.9%) survived with favorable neurological outcome upon 
discharge. While this elicits a net 0.3% improvement with administration of epinephrine, 
the study failed to find a statistically significant improvement in survival with favorable 
neurological function upon hospital discharge (OR: 1.18, 95% CI: 0.86-1.61). 
Additionally, survival with poor neurological outcome was more common in the 
epinephrine group (39 of 126 surviving patients at discharge, 31%) than the placebo 
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group (16 of 90 surviving patients at discharge, 17.8%). No 95% CI was used for poor 
neurological outcome.  
 While this study was an improvement into the potential neurological effects 
epinephrine may have during cardiopulmonary resuscitation, there were many shortfalls 
in the study. The primary outcome of this study was 30-day survival, which was also 
used as the parameters to determine the sample size. Data collection was halted at 8,000 
subjects when a 95% CI OR of 1.06-1.82 for 30-day survival with epinephrine was 
achieved. As a result, this study was unable to prove a statistically significant 
improvement in favorable neurological outcome with administration of epinephrine to 
placebo. Additionally, there were more survivors with epinephrine leading to a potential 
survivor bias. Thus, individuals who would not have survived without epinephrine were 
included for data collection of the neurological outcome in the epinephrine group only. 
Another bias is that the neurological outcome was determined by research paramedics 
subjectively. While the paramedics were blinded when they evaluated neurological 
outcome, they were still subject to observer bias. Lastly, there is a question of the 
generalizability of this study. The study reports the average elapsed time prior to 
ambulance arrival was 6.6 minutes and 13.8 minutes until epinephrine or placebo 
administration. This could mean that the window of benefit from epinephrine could have 
passed by or been limited in some cases. Therefore, these results cannot be applied to in-




Prehospital Epinephrine Use and Survival Among Patients with Out-of-Hospital 
Cardiac Arrest18 
To date there have been few studies that have investigated the neurological impact that 
epinephrine may have on patients suffering cardiac arrest. However, these studies have 
had conflicting results. A prospective, nonrandomized, observational study by Hagihara  
et. al. is one such study that examined this issue 
This study by Hagihara et. al. included 417,188 out-of-hospital cardiac arrests in 
Japan. Adults older than 18 were included in the study. Cases that had 60 minutes elapsed 
between the emergency call and EMS arrival or cases with more than 480 minutes 
elapsed between call and hospital arrival were excluded from the study. In this 
nonrandomized observational study, data was collected on out-of-hospital cardiac arrests 
from 2005-2008. From 2005 until April 2006, emergency technicians within ambulances 
were unable to administer IV epinephrine. Thus, all heart attacks in this study occurring 
before April 2006 were assigned to not receive epinephrine. Those patients after April 
2006 included some technicians assigned to administer epinephrine. Neurological 
outcome was assessed a month after the cardiac arrest with both the Glasgow-Pittsburgh 
Cerebral Performance Category (CPC) Scale and the Overall Performance Category 
(OPC) Scale. Both scales rate neurological status on a scale of 1-5 with a score of 1 or 2 
being considered a favorable neurological outcome. These scores were then used to 
calculate Odds Ratios with 95% confidence intervals. These results were then adjusted 
for confounders such as age, sex, time until EMS arrival and whether or not CPR was 
initiated by or witnessed by bystanders. 
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In this prospective observational study 15,030 patients were administered 
epinephrine, while 402,158 patients were included that received no epinephrine. Out of 
the 15,030 patients who received epinephrine, 205 (1.4%) patients survived with a CPC 
score of 1 or 2 and 211 (1.4%) survived with an OCP score of 1 or 2. Those who did not 
receive epinephrine, 8,903 (2.2%) had a CPC score of 1 or 2 and 8,831 (2.2%) had an 
OCP score of 1 or 2. This in turn yields an adjusted 0.61 (95% CI: 0.53-0.70) and an 
adjusted OR of 0.31 (95% CI: 0.26-0.36) when using the CPC scale for the favorable 
neurological outcome with epinephrine. When adjusted for covariates, this yielded an 
adjusted OR of 0.31 (95% CI: 0.26-0.36) when using the CPC scale. This was similarly 
represented with the OPC scale with an unadjusted OR of 0.63 (95% CI: 0.55-0.73) and 
an adjusted OR of 0.32 (95% CI: 0.27-0.38). Thus, this study found a large statistically 
significant negative association between epinephrine administration and favorable 
neurological outcome.  
This study is one of a few that explored how epinephrine may impact neurological 
outcome in cardiac arrest patients. While this study found a large statistically significant 
negative association with favorable neurological outcome and epinephrine administration 
during cardiopulmonary resuscitation, this study is limited by the observational nature of 
the study. Thus, any finding is restricted to an association rather than eliciting a causal 
relationship between the independent and dependent variables, as the identified 
relationship might be due to residual confounding. In addition to the two groups being 
separated by management techniques, they were also separated by time. More than half 
of the cases without epinephrine occurred before April 2006, while all of the epinephrine 
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cases occurred after. While this doesn’t inherently confound the results, it is impossible 
to account for any environmental or medical change impacts that may have occurred in 
the two years separating the majority of cases between the two groups. Similar to other 
studies that have investigated the relationship between epinephrine and survival with 
favorable neurological outcome, this study solely relies on a subjective neurological 
assessment for data. Thus, opening up the study to observer bias. An additional 
confounder in this study is that CPR was never terminated prior to hospital presentation, 
as there was no physician inside the ambulance. Patients who did not achieve ROSC in 
the ambulance were brought to the hospital, where they may have received epinephrine 
after the prehospital care had been concluded.  
Additionally, other studies that have investigated this relationship have found 
contradicting results to those of this study. While those studies found a statistically 
insignificant improvement in neurological outcome, some of them were randomized 
controlled trials that yield results less likely due to do confounding. However, these 
studies tended to have survival to hospital discharge as the primary outcome leaving too 
small of a sample size to find any significant improvement. Therefore, to date there is 
still no randomized controlled trial that has elicited a statistically significant change in 
neurological outcome as a function of epinephrine. 
 
Intravenous Drug Administration During Out-of-Hospital Cardiac15 
While there have been studies that investigated how the use of epinephrine affects 
neurological outcome, previous studies that compared epinephrine to placebo in out-of-
hospital cardiac arrests failed to account for the preparation required to administer the 
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epinephrine. To use epinephrine during a cardiac arrest, one must first establish 
intravenous access, which may divert resources and attention away from quality chest 
compressions in the setting of an ambulance. This in turn may confound epinephrine’s 
effect by limiting the quality and effectiveness of the chest compressions, while 
intravenous access is established. A randomized controlled study by Olasveengen et. al. 
examined epinephrines neurological impact by comparing epinephrine and CPR without 
epinephrine or IV access. 
This randomized controlled trial included 851 patients who suffered out-of-
hospital cardiac arrests in the Oslo, Norway area. These patients were randomly assigned 
to receive epinephrine after IV access was established or to not receive epinephrine or an 
IV. Those patients who did not receive an IV or epinephrine had IV access established 5 
minutes after ROSC had been achieved. Patients with cardiac arrests due to asthma or 
anaphylactic shock were excluded. Cardiac arrests that were witnessed by EMS or those 
resuscitations that involved physicians not associated with the ambulance team were 
excluded from the study. Confounders were accounted through the Mantel-Haenszel test. 
While the primary outcome was survival to hospital discharge, a secondary outcome was 
survival to hospital discharge with favorable neurological outcome. Neurological 
function was scored subjectively on a scale of 1-4 for cerebral performance. 
This study found that 9.8% of the intravenous group survived with favorable 
neurological function while the non-intravenous group had a survival with favorable 
neurological rate of 8.1% (OR: 1.16, 95% CI: 0.74-1.82, p=0.45). While this study found 
a net improvement of 1.7% in survival with favorable neurological outcome, this 
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improvement in neurological outcome was not significantly significant. Therefore, this 
study was unable to prove that there was any significant change in neurological function 
by eliminating the time and resources necessary for epinephrine during CPR. 
This study was the first to investigate epinephrine’s effect on neurological 
outcome during CPR, while accounting for the preparation needed for administering 
epinephrine. However, this study did not compare the intravenous and non-intravenous 
group to a placebo with intravenous placement group. This would have allowed for a 
comparison between a placebo with intravenous access and patients who did not receive 
intravenous access. Therefore, this study could not determine whether there was any 
difference in outcome as a function solely due to the preparation of epinephrine and the 
dedication of time and resources that come with it. Additionally, the primary endpoint 
was survival to hospital discharge, which was used to determine the population size of 
the study. This in turn could be the reason why no statistically significant difference was 
found in neurological outcome at hospital discharge.  
This randomized controlled trial by Olasveengen et. al., as other studies that 
investigated neurological outcome following a cardiac arrest, assessed neurological 
function only subjectively. This in turn allowed for a potential observer bias. Another 
potential confounding variable is that the intravenous group received more defibrillators 
and were resuscitated for a longer period of time on average. This could be due to a 
multitude of reasons such as a lack of provider blinding resulting in difference in care, 
effects of epinephrine resulting in a greater likelihood of achieving ROSC or underlying 
differences in the patients within the two groups. Lastly, only 75% of cases had quality of 
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chest compressions assessed for. A more complete analysis of compression quality would 
have helped to normalize the differences between the two groups. 
 
The Association of the Average Epinephrine Dosing Interval and Survival with 
Favorable Neurologic Status at Hospital Discharge in Out-of-Hospital Cardiac 
Arrest14 
Since the safety of epinephrine has come into question in recent years, some studies have 
investigated potential variables that could affect epinephrine’s efficacy and neurological 
impact. While studies comparing epinephrine to placebo have not been approved in the 
United States, a study by Grunau et. al. explored whether the frequency of standard dose 
epinephrine during cardiopulmonary resuscitation could impact the neurological outcome 
of patients after suffering cardiac arrest. This was the first study to compare epinephrine 
interval and survival with favorable neurological outcome. 
This observational study involved 15,909 patients from 10 regional centers across 
North America, including the United States and Canada. Only nonpregnant and 
nonprisoner adults (18+) in out-of-hospital cardiac arrests were included. To be included 
in the study, patients must have received at least 2 doses of epinephrine and have had at 
least 10 minutes of CPR following administration of the first epinephrine dose. Cases due 
to asphyxiation and trauma were excluded. Additionally, patients with an existing 
tracheostomy, those who were placed on a mechanical chest-compression device and 
those who suffered a rearrest were not included. This study was performed in conjunction 
with the Trial of Continuous or Interrupted Chest Compressions during CPR with the 
Resuscitation Outcome Consortium. While the independent variable in this patient 
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population was continuous chest compressions or interrupted chest compressions for 
ventilation, the entire CPR process was recorded for each patient including epinephrine 
administration time interval.  
The data collected on each patient was then used for this observational study to 
investigate how the frequency of epinephrine administration impacted survival with 
favorable neurologic status at hospital discharge. The epinephrine dosing interval was 
calculated by taking the time from the first epinephrine dose to the termination of CPR 
divided by the number of epinephrine doses. Epinephrine dosing intervals were then 
placed into 4 groups: <3 min, 3-4 minutes, 4-5 minutes and >5 minutes. Neurological 
outcome was evaluated using a modified Rankin scale of 0-6 with favorable neurological 
outcome defined as a score <3.  
This study found that the group with an epinephrine dosing of <3 minutes that 
included 2,059 patients had the highest survival rate with favorable neurological outcome 
of 5.0% (95% CI: 4.1%-6.0%). The 3-4 minute dosing interval group of 4,136 subjects 
yielded a survival with favorable neurological outcome in 2.1% of cases (95% CI: 1.7%-
2.6%). The 4-5 minute dosing interval group of 4,463 patients showed a survival with 
favorable neurological outcome rate of 1.4% (95% CI: 1.1%-1.8%). Lastly, the >5 minute 
dosing interval group including 5,251 patients yielded a survival with favorable 
neurological outcome in 1.4% of cases (95% CI: 1.1%-1.7%). 
These results indicate that there is a contiguous trend in improvement of 
neurological function at hospital discharge with a shorter dosing interval of epinephrine. 
While there is statistically significant improvement in >3 minute dosing interval group in 
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terms of survival with favorable neurological outcome in comparison to longer dosing 
intervals, this study failed to show any statistically significant difference among the other 
groups. Therefore, the only distinction between dosing intervals of epinephrine during 
CPR that can be determined is that, if epinephrine is used, there is an association with 
improved neurological function when it is administered in an interval of <3 minutes. 
This observational study by Grunau et. al. is the first study to investigate how the 
dosing interval of epinephrine might affect neurological status in cardiac arrest patients. 
However, there are several shortfalls in this study. This observational study was based on 
a population that was involved in a randomized control study for another variable. As an 
observational study, there can be no determination of a causal relationship between the 
variable and the outcome, rather only an association. This in turn means that there could 
be a confounding variable responsible for the elicited difference between the shortest 
dosing interval group and the rest such as the shorter interval could be associated with 
more experienced providers, more aggressive resuscitation strategy or higher quality 
compressions. Another complication from the observational basis of this study is that the 
epinephrine intervals were calculated afterwards rather than subjects being randomly 
assigned to groups with epinephrine administered at a present and more exact time 
interval.  
Additionally, this study did not have a group that did not receive epinephrine for a 
comparison. Therefore, while there was an improvement with more frequent dosing, it 
fails to show that epinephrine improves neurological function when compared to placebo. 
This raises the question of whether there is improvement in neurological function with 
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more frequent epinephrine dosing or if there is less harm to neurological function when 
given more frequently. Like other studies investigating neurological outcomes as a result 
of epinephrine, evaluation of neurological function was done in a subjective fashion 
which ultimately allows for observer bias.   
Lastly, there is a question of generalizability. Only out-of-hospital arrest subjects 
who waited over 5 minutes for EMS arrival were included. Therefore, these findings 
cannot be extended to all demographics and in hospital arrests, as there is much shorter 
delay for CPR initiation in hospital. These findings also may not be applicable to all 
cardiac arrest types as only about 20% of the cases had a shockable rhythm, thus placing 
more weight on the non-shockable rhythm subgroup. This study also excluded subjects 
who: received fewer than 2 doses of epinephrine, had a rearrest following the initial 
cardiac arrest in EMS care, had an existing tracheostomy or were placed on a mechanical 
compression device. Therefore, there is subject bias as a large proportion of patients were 
excluded that also received epinephrine during CPR. 
 To date there has not been an RCT that compared epinephrine to placebo with the 
primary outcome being favorable neurological outcome. Furthermore, every study to use 
favorable neurological outcome as one of the endpoints has only used a subjective 
evaluation as a means to characterize neurological status. This in turn leaves several 
questions unanswered concerning epinephrine’s safety in terms of its potential 
neurological impact with anoxic brain injury. Lastly, there is limited data to characterize 
what these neurological deficits are or any comparison in areas of the brain affected by 





This double-blind RCT will compare the use of epinephrine and placebo in out-of-
hospital cardiac arrests. This study will use objective means of evaluating neurological 
outcome, which will be the primary outcome of this study. This evaluation will consist of 
a neurological assessment by a hospital provider, Montreal cognitive assessment (MoCA) 
and magnetic resonance imaging (MRI). By focusing on neurological outcome and using 
objective analysis, this study aims to find a causal relationship between the use of 
epinephrine in cardiac arrest and neurological outcome. 
 
Study population and sampling 
This study will involve out-of-hospital cardiac arrests in the United Kingdom over 2 and 
a half years. Patients suffering a cardiac arrest who are 18 years of age or older will be 
included in the study. These subjects will be randomly assigned to either the placebo or 
epinephrine group based on pre-packed syringes with blinded contents. Patients with 
existing central lines or existing advanced airways such as a tracheostomy will be 
excluded as that will remove steps within the ACLS protocol, potentially confounding the 
results. 
 In order to determine the impact that epinephrine has on neurological outcome, 
parameters will be an alpha level of .05 and beta level of .2. A study by Perkins et al was 
used as a reference for determining the proper sample size that will need to determine the 
impact that epinephrine has on neurological outcome in cardiac arrest patients. In this 
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study of 8007 patients, 8001 of these patients were tested for favorable neurological 
effort. Out of the 4007 subjects placed in the epinephrine group, 2.2% of patients were 
found to be discharged with favorable neurological outcome. In the placebo group, 1.9% 
of the 1994 patients were found to be discharged with favorable neurological outcomes. 
This yields an odds ratio of 1.1614 and risk ratio of 1.1579 for favorable neurological 
status with epinephrine. Through normal approximation of the z statistic with continuity 
correction, this yields an estimated sample size of 71,378 for this study to have the power 
needed to detect epinephrine’s effect on the neurological status of cardiac arrest patients.  
 
Treatment  
All patients enrolled in this study will be randomly assigned to receive either epinephrine 
or placebo. The ACLS protocol will be followed in both groups including CPR, rhythm 
checks with possible defibrillation depending on the presenting rhythm and 
antiarrhythmic medications, when indicated. However, ambulances will be supplied with 
prepackaged syringes of either epinephrine or placebo to which the paramedic who will 
be administering them will be blinded. All syringes in the kit will be of the same contents 
so that each subject will receive only epinephrine or only placebo with every ensuing 
administration.  
With the exception of the use of epinephrine or placebo, all cases will follow the 
ACLS protocol until ROSC is achieved or until the ambulance arrives at the hospital. As 
the prepackaged syringes will be supplied and administered by the ambulance service, 
once the patient arrives at the hospital and the emergency personnel take over, the cardiac 
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arrest will be treated as hospital protocol dictates. Surviving patients will be admitted to 
the hospital and follow post-arrest treatment as indicated by hospital personnel. Full 
neurological assessment will be completed prior to hospital discharge. 
 
Study variables and measures 
The independent variable of this study will be the use of epinephrine. The remainder of 
the ACLS protocol between the placebo and epinephrine groups will remain identical but 
certain aspects of the protocol will vary as a result of the duration and reason for 
termination of the ACLS protocol. Some patients will have longer transport times in an 
ambulance and some will have a short course of ACLS, if ROSC is achieved. Therefore, 
this study will monitor and record other data such as: location of MRI findings, length of 
resuscitation, number of epinephrine administrations, number of defibrillators and reason 
for halting. Other clinical criteria that will be documented include: presenting rhythm, 
cause of arrhythmia, time elapsed prior to EMS arrival and whether or not bystander CPR 
was initiated. 
The primary outcome of this study is survival to hospital discharge with favorable 
neurological status. In order to assess this, three measurements will be taken. Then after 
data collection is complete for a subject, these three measurements will yield individual 
scores that will be added together, giving a combined score that will be used for the final 
data analysis. Other secondary outcomes include achievement of ROSC, survival to 
hospital admission, survival to hospital discharge, 3-month survival and 3-month survival 
with favorable neurological status. Neurological status will be assessed with a disability 
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evaluation and scoring on a modified Rankin scale, MoCA testing and MRI. Survival will 
be recorded for each endpoint listed above and averages for each group will be compiled. 
Further analysis will be completed to determine rates for subgroups such as presenting 
rhythm and cause of arrhythmia. 
 
Recruitment 
Recruitment in studies of epinephrine and placebo provides quite a challenge considering 
epinephrine is a standard of care medication for a life-threatening condition in the United 
States. However, epinephrine was adopted as the gold standard treatment in the United 
States prior to its efficacy and safety being proven. While it would be arguable ethical to 
carry out this experiment, approval for this study would be difficult in the United States, 
despite having limited support from clinical trials. However, the study by Perkins et. al. 
was recently performed in the United Kingdom through the National Health Service 
(NHS) ambulance services under similar circumstances.  
Having a similar study that investigated epinephrine’s efficacy in the same area 
provides an opportunity for this study to also be conducted under the same area with the 
same laws and restrictions. This proposed study hopes to examine epinephrine’s safety 
concerns that were originally raised by the previous study. The study by Perkins et. al. 
also randomly assigned patients in the United Kingdom to receive either epinephrine or 
placebo based on prepackaged syringes, providing a smooth transition into this study. 
The difference for this study is that a larger sample size is required and the primary 
outcome would be neurological outcome as opposed to survival. Thus, while the previous 
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study examines epinephrine’s efficacy, this study will be performed under a similar 
manner to investigate its safety. 
 
Data collection 
The first neurological assessment will be completed on the last day of hospital 
admission. This will be modeled after previous studies that evaluated neurological status. 
Using a modified Rankin scale (Table 2), the patient’s neurological symptoms will 
receive a graded score of 0-6 based on an assessment where a score of 0 is defined as 
absent symptoms and a score of 6 represents a deceased patient. The modified Rankin 
score evaluates a patient based on their ability to complete activities of daily living in 
order to characterize their disability. 
Table 2: Modified Rankin Score for Disability 
Score Definition 
0 Absent symptoms 
1 No major disability 
2 Slight disability, able to self-care 
3 Moderate disability, requires some daily assistance 
4 Moderate-severe disability, unable to walk independently 
5 Severe disability, requires constant nursing care 
6 Death 
 
The second measurement is based on the Montreal Cognitive Assessment 
(MoCA). This standardized test measures a patient’s executive functioning, memory, 
attention, language, abstract thinking and orientation. Traditionally the MoCA has been 
used to assess patients for cognitive impairment or dementia; however, recently it has 
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also been used to evaluate the mental status of Parkinson's disease and stroke patients in 
several research studies. By adding this measurement, we will be able to more thoroughly 
assess for neurological deficits and to further characterize the ailments in both the 
placebo group and epinephrine group. By determining the exact areas and trends of injury 
associated with each group, we hope to identify those injuries associated with cardiac 
arrest and those directly attributable to epinephrine. The MoCA has 5 results based on a 
score out of a maximum of 30 (Table 3) to stratify the degree of impairment. For the 
purpose of this study, we have added an additional score of 5 for those patients who will 
not survive to take the MoCA test38. 
Table 3: MoCA Scores 
Scores Interpretation Study Score 
>26 Normal 0 
18-26 Mild Cognitive Impairment 1 
t11-17 Mild dementia 2 
t6-10 Moderate dementia 3 
<6 Severe Dementia 4 
N/A death 5 
 
The last mode of measuring neurological status is an MRI. The methods of this 
study are based on the findings of a study by Wijdicks et al that examined the MRI 
findings in comatose survivors of cardiac arrest. Similar to the methods of Wijdicks et al, 
this study will use MRI with several settings including: T1-weighting, T2 weighting, flair 
and DW. Images will be taken in both axial and sagittal view sequences. The data 
collected by DW settings for both sagittal and axial views will be used to calculate the 
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Apparent Diffusion Coefficient (ADC). The ADC can be quantified specified to specific 
structures of the brain and represents ischemic or anoxic brain damage22. Therefore, one 
could theoretically map the extent of damage to the brain and localize where the damage 
lies.  
The brain structures that will be assessed for ADC and underlying anoxic brain 
damage and assessment include: cerebellum, pons, basal ganglia, caudate, thalamus, 
splenum, frontal lobe, temporal lobe, parietal lobe, occipital lobe, insular cortex, 
hippocampus and white matter.  For each structure, normal ADC values range from 700 - 
800 x 10-6 mm2/s with decreased values implicating anoxic brain damage. In the study by 
Wijdicks et al, patients ranged between 0-9 damaged brain structures. One important 
point is that these patients were all comatose and are more likely than the average cardiac 
arrest survivors to show such extensive damage. As a result, the scale of this study will 
use a scale, similar to that of the modified Rankin scale, where patients are given a score 
of 0-6 to stratify the extent of damage found on MRI. Patients will be given one point for 
each damaged brain structure with 0 being no abnormal ADC values and a score of 6 
representing six or more affected structures. This process will be performed on both 
hemispheres of the brain and each affected hemisphere structure will be counted as a full 
point.  
All three scores will be combined for final analysis. Any combined score less than 
or equal to 8 will be considered favorable neurological status. These assessments and 
scores will be completed at two separate timepoints, prior to hospital discharge and 3 
months following the initial cardiac arrest. Additionally, survival rate to ROSC, hospital 
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admission and 3 months will be recorded. This study will also establish subgroups of 
presenting rhythms, underlying cause of arrhythmia, number of epinephrine doses, 
duration of resuscitation and whether CPR was initiated by bystanders. MoCA hardcopies 
will be scanned and stored in a database. MRI readings and ADC data will be sent to a 




The scores from the disability evaluation, MoCA and MRI will combine to a total score 
for each subject. Each subject with a score equal to or less than 8 will qualify as favorable 
neurological outcome. Individual cases will be added together within their respective 
groups to yield the risk of survival to hospital discharge with favorable neurological 
outcome for patients who receive epinephrine and those who do not. These will then be 
used to find a risk ratio between favorable neurological outcome as a result of 
epinephrine administration. After a risk ratio is found, a 95% confidence interval will be 
used to illustrate if a statistically significant difference is found between the two groups.  
 Secondary outcomes will also be analyzed similarly. Three-month survival with 
favorable neurological status will require follow-up MOCA, disability assessment and a 
repeat MRI at that point. The statistical analysis will be performed identically to that of 
the primary outcome. However, it is likely that this study will be underpowered to reach a 
statistically significant difference at 3-month survival with favorable neurological 
outcome as some patients are expected to not survive between hospital discharge and 3-
month follow-up. The other secondary outcomes will be analyzed and used to determine 
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a risk ratio that will use a 95% confidence interval to illustrate any significant differences 
between the two groups. These risk ratios and confidence intervals will be used to 
illustrate epinephrine’s role in achieving ROSC, survival to hospital discharge and three-
month survival. 
 Lastly, subgroups will be established for each of these proposed outcomes. By 
looking at variables such as: presenting rhythm, cause of arrhythmia and whether or not 
bystander CPR was initiated prior to EMS arrival; an association between improved or 
poor outcomes as a result of epinephrine can be established under more specific 
conditions. These subgroups will undergo the same statistical analysis as the main 
epinephrine and placebo groups, although it is likely that few significant differences will 
be found as the study is powered towards larger samples. However, by exploring these 
details this study hopes to create potential opportunities to explore a means of optimizing 
epinephrine’s use in cardiac arrest. 
 
Timeline and resources 
As discussed above this study requires 71,378 subjects in order to reach the power it 
needs to fulfill its objective. There are an estimated 30,000 out-of-hospital cardiac arrests 
in the United Kingdom annually, which means that it would take approximately two and 
a half years to achieve the desired sample size of this study. Additionally, IRB approval 
will likely require one or two months. 
The study intervention will start with training the paramedics of participating 
ambulance services. After training is completed, the intervention can proceed as 
discussed. Cardiac arrest patients will be randomly assigned to one of the two groups and 
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EMS will report the data collected during the resuscitation phase of treatment to a study 
coordinator. Follow-up prior to hospital discharge and at three months will be headed up 
by co-investigators and their student workers. While the MoCA and disability screening 
require minimal resources, the MRI will require additional assets. While it is the hope 
that an MRI of the brain will be taken prior to hospital discharge, there will be a necessity 
for study coordinators to organize with the patient’s primary team to order the 
appropriate imaging. When all data is collected, a statistician will be needed to analyze 
the results. The interventional phase of the study will be terminated once the study has 
reached its goal sample size. 
 
Institutional Review Board 
This study is appealing to a full board in order for approval to withhold a standard of care 
medication from study participants. Epinephrine has been continually used without the 
appropriate studies to support its efficacy and even fewer to support its safety. As a 
result, countless patients have been treated with a medication with a theoretical benefit 
for a life-threatening condition. Epinephrine has not been proven to have any long-term 
benefit to patients and its safety has not been proven. For this reason, patients would not 
be subjected to undue risk by withholding this medication in our assessment of 
epinephrine’s impact on neurological outcome of cardiac arrest patients. Through 
investigating this sensitive topic, this study hopes to provide answers to the safety 





This will be the first placebo-controlled RCT of epinephrine to use favorable neurological 
outcome as the primary outcome with objective means of analyzing the patient’s 
neurological status. However, with such implications, there come limitations. Out of the 
studies that were researched in preparation for this proposal, none that examined 
neurological outcome were properly powered to effectively do so. As a result, the 
proposed sample size is based on an underpowered study by Perkins et al. This leaves the 
potential for underpowering in our own study as well. However, this study will have an 
advantage in the sense that more objective data will be taken to analyze neurological 
outcome. This has two benefits; the first is that it minimizes the potential for observer or 
number bias that comes from subjective evaluations using a modified Rankin score. 
Secondly, by including more data, it is likely to decrease bias within this study. 
 Another advantage of this study is its inclusion of MRI. By including imaging 
with the neurological assessment and MOCA, one can directly trace the anatomical 
damage to its clinical manifestation. When this method is integrated into a blinded trial, 
the imaging and ensuing neurological outcome will further support a causal relationship 
between those neurological deficits that are due to cardiac arrest and those that are due to 
the use of epinephrine. 
 One shortfall in this study is that the protocol will only extend to the allotted time 
that the patient is under the care of the paramedic and the rest of the EMS team. Once the 
patient is accepted into the care of the emergency department team, patients in the 
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placebo group may receive epinephrine. This complication is difficult to avoid as it 
would require coordination between all participating ambulance services and the 
hospitals to which the patients are brought, exceeding the capabilities of this study. While 
this is a significant potential misclassification bias, the results will still be applicable to 
out-hospital cardiac arrest treatment as this study has no aim to alter the current treatment 
of in-hospital cardiac arrests.  
 Another potential shortfall of this study is the generalizability. This study only 
includes out-of-hospital cardiac arrests. Out-of-hospital cardiac arrests were selected over 
in-hospital arrests as they have a larger incidence, EMS covers a wider geographic area 
of coverage than a hospital and because epinephrine studies have had poorer results in 
out-of-hospital settings. As a result, the data collected from this study cannot be 
generalized to in-hospital cardiac arrests. However, pending the results of this study, 
further research into cardiac arrests in the hospital setting may be warranted. 
 While there is a question to the generalizability of the findings of this study, the 
additional information that is collected by it may impact how epinephrine is used in the 
future. Underlying cardiac rhythms, causes of underlying rhythm and number of 
epinephrine doses given may also reveal an advantage or disadvantage to using 
epinephrine under certain circumstances. For instance, epinephrine may have greater 
efficacy in non-shockable rhythms as there will be fewer breaks in CPR, which in turn 
may result in greater neurological function in those patients who presented with a non-
shockable rhythm and given epinephrine. Unfortunately, a shortfall would be that this 
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study is not powered to find a difference in neurological outcomes of these subgroups, 
meaning that several of these groups will fail to produce a statistically significant. 
 
Summary 
Epinephrine has been used for the treatment of cardiac arrests throughout modern 
medicine, despite limited evidence to support either its efficacy or safety. Since then, 
several studies have investigated its efficacy, proper dosage and interval of 
administrations. However, these studies have produced conflicting results concerning the 
efficacy of epinephrine. While these studies do show modest benefit in achieving ROSC 
and survival to hospital admission with epinephrine, they have failed to show any 
consistent long-term benefit to survival, including survival to hospital discharge or three 
month survival. 
In recent years, epinephrine’s safety has also come into question. While there is a 
proposed mechanism of beta-adrenergic and alpha-adrenergic stimulation resulting in 
increased blood pressure and heart rate to increase the likelihood of ROSC, there is also a 
proposed mechanism for further brain damage by increased platelet activation and 
myocardial oxygen demand. This proposed mechanism suggests that epinephrine could 
trigger a cascade of events that lead to increased risk of a stroke and decreased oxygen 
levels to the brain, further exacerbating the anoxic damage. 
This proposed harmful mechanism warrants further investigation so that proper 
assessment of epinephrine’s risks and benefits can be performed. While there are several 
studies that investigate the efficacy of epinephrine on survival, there are limited studies 
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that look into the neurological impact and morbidity associated with it. This study aims to 
provide the necessary data for this assessment by further exploring and characterizing the 
neurological impact of both cardiac arrest and epinephrine. 
 
Clinical and/or public health significance 
To date there is no RCT that compares placebo to epinephrine in cardiac arrest patients 
with neurological outcome as the primary outcome. Additionally, in all studies with 
favorable neurological outcome as a secondary outcome the analysis of neurological 
outcome was based on subjective evaluation of the patient. Placebo-controlled studies of 
epinephrine out-of-hospital cardiac arrests have yielded conflicting results when it comes 
to survival past hospital admission.  
While it is unlikely that this study will provide new evidence on epinephrine’s 
impact on the mortality of cardiac arrests, it will undoubtedly improve our understanding 
of the associated morbidity and how epinephrine might impact it. In addition to 
expanding our knowledge on the neurological outcome of cardiac arrest patients who did 
or did not receive epinephrine, we will understand which regions of the brain are most 
affected and the mechanisms behind their injury. With this new information, 
epinephrine’s role in cardiac arrest can be reevaluated and potential improvements to use 
or complications can be explored. 
If this study elicits an associated poor negative neurological outcome, it will 
suggest that epinephrine may not be as safe as first thought. This would then raise the 
question of whether or not the mortality benefit outweighs the potential poor neurological 
impact it may have. If this study fails to illustrate a negative effect of epinephrine on 
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neurological outcome in cardiac arrest patients; the results of the study would suggest 
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